Citations

Clear

5 citation(s) found for "Schmalfeldt, Barbara".

Dilution of Molecular–Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer
Kommoss, Stefan , Tourani, Roshan , Grandelis, Anthony , Uppendahl, Locke , Aliferis, Constantin , Burges, Alexander , Wang, Chen , Canzler, Ulrich , Belau, Antje , Prader, Sonia , Hanker, Lars , Ma, Sisi , Hilpert, Felix , Schneider, Stephanie , Kimmig, Rainer , Kurzeder, Christian , Schmalfeldt, Barbara , Braicu, Elena Ioana , Harter, Philipp , Dowdy, Sean C. , Winterhoff, Boris , Pfisterer, Jacobus , Uppendahl, Locke , Burges, Alexander , Wang, Chen , Heitz, Florian , Ma, Sisi , Ataseven, Beyhan , Sehouli, Jalid , Bois, Andreas du

Mayo Clinic

Clinical Cancer Research | September 16, 2019 | Volume: 26 | Issue: 1 | Pages: 213-219

10.1158/1078-0432.ccr-19-1741 | PMID 31527166 Get It

Abstract Purpose: Predicting surgical outcome could improve individualizing treatment strategies for patients with advanced ovarian cancer. It has been suggested earlier that gene expression signatures (GES) might harbor the potential to predict surgical outcome. Experimental Design: Data derived from high-grade serous tumor tissue of FIGO stage IIIC/IV patients of AGO-OVAR11 trial were used to generate a transcriptome profiling. Previously identified molecular signatures were tested. A theoretical model was implemented to evaluate the impact of medically associated factors for residual disease (RD) on the performance of GES that predicts RD status. Results: A total of 266 patients met inclusion criteria, of those, 39.1% underwent complete resection. Previously reported GES did not predict RD in this cohort. Similarly, The Cancer Genome Atlas molecular subtypes, an independent de novo signature and the total gene expression dataset using all 21,000 genes were not able to predict RD status. Medical reasons for RD were identified as potential limiting factors that impact the ability to use GES to predict RD. In a center with high complete resection rates, a GES which would perfectly predict tumor biological RD would have a performance of only AUC 0.83, due to reasons other than tumor biology. Conclusions: Previously identified GES cannot be generalized. Medically associated factors for RD may be the main obstacle to predict surgical outcome in an all-comer population of patients with advanced ovarian cancer. If biomarkers derived from tumor tissue are used to predict outcome of patients with cancer, selection bias should be focused on to prevent overestimation of the power of such a biomarker. See related commentary by Handley and Sood, p. 9
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO‐OVAR OP7).
Mahner, Sven� , Burges, Alexander , Reuß, Alexander , Kraemer, Bernhard , Schmalfeldt, Barbara, Lampe, Bjoern, Fotopoulou, Christina , Lécuru, Fabrice , Querleu, Denis , Greggi, Stefano , Colombo, Nicoletta , Harter, Philipp , Heitz, Florian , Sehouli, Jalid , Schnelzer, Andreas , Wimberger, Pauline , Guyon, Frédéric , Aletti, Giovanni , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS5602-TPS5602

10.1200/jco.2017.35.15_suppl.tps5602 Get It

TPS5602 Background: Primary cytoreductive surgery (PDS) followed by chemotherapy has been considered as standard management for advanced ovarian cancer patients (pts) over decades. An alternative approach of interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) was subsequently reported by two randomized phase III trials (EORTC‐GCG, CHORUS). Owing to important limitations of these studies, especially regarding surgical quality, optimal timing of surgical therapy in advanced ovarian cancer is still unclear. Methods: TRUST is an international open, randomized, controlled multicenter trial investigating overall survival (OS; primary endpoint) after PDS vs NACT and subsequent IDS in pts with FIGO stage IIIB‐IVB ovarian, tubal, and peritoneal carcinoma. Secondary objectives are safety of complete tumor resection, progression‐free survival and quality of life (QoL) as well as surgical morbidity. In order to guarantee adequate surgical quality, participating centers need to fulfill specific quality assurance criteria (e.g. ≥50% complete resection rate in upfront surgery for FIGO IIIB-IV pts, ≥36 debulking-surgeries/year) and agree to independent audits by TRUST Quality committee delegates. A 1:1 randomization to PDS or NACT followed by IDS stratified by center and age‐ECOG combination (ECOG 0 and age ≤65 years vs ECOG > 0 or age > 65 years) is performed. Pts in the PDS arm will undergo surgery followed by 6 cycles of platinum-based chemotherapy, whereas pts in the IDS arm will be treated with 3 cycles of NACT after histologic confirmation of the disease, followed by IDS and subsequently 3 cycles of platinum-based chemotherapy. Intention of surgery for both groups will be complete tumor resection as per guideline recommendations. Health related QoL will be assessed using the EORTC QLQ‐C30, QLQ‐OV28, and EQ‐5D‐3L questionnaires. For sample size planning, we considered a prolongation of median OS from 45 months in the IDS arm to 60 months in the PDS arm (HR 0.75) as clinically relevant. 380 events are needed to obtain a power of 80% in two‐sided log-rank test with significance level of 0.05. The primary analysis will be done in the ITT‐population of 686 randomized pts. By Feb 3 2017, 46 pts were randomized. Clinical trial information: NCT02828618.
Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial.
Kommoss, Stefan , Winterhoff, Boris , Aliferis, Constantin , Burges, Alexander , Canzler, Ulrich , Wang, Jinhua , Belau, Antje , Hanker, Lars , Ma, Sisi , Hilpert, Felix , Tourani, Roshan , Kimmig, Rainer , Kurzeder, Christian , Schmalfeldt, Barbara , Dowdy, Sean C. , Pfisterer, Jacobus , Heitz, Florian , Wang, Chen , Ma, Sisi , Sehouli, Jalid , Bois, Andreas du

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5550-5550

10.1200/jco.2018.36.15_suppl.5550 Get It

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Sucheston‐Campbell, Lara, Cannioto, Rikki , Clay‐Gilmour, Alyssa , Etter, John Lewis , Eng, Kevin H., Liu, Song , Battaglia, Sebastiano , Szender, J. Brian, Minlikeeva, Albina N. , Joseph, Janine M. , Mayor, Paul , Abrams, Scott I. , Wallace, Paul K. , Soh, Kah Teong , Zsíros, Emese , Beckmann, Matthias W. , Bruegl, Amanda , Campbell, Ian , Campbell, Shawn, Chenevix‐Trench, Georgia , Diergaarde, Brenda , Doerk, Thilo, Eccles, Diana , Engelholm, Svend Aage, Fasching, Peter A. , Gayther, Simon A. , Goodman, Marc T. , Harter, Philipp , Hein, Alexander , Heitz, Florian , Hillemmanns, Peter, Høgdall, Claus , Høgdall, Estrid , Huzarski, Tomasz , Jensen, Allan , Johnatty, Sharon E. , Jung, Audrey , Klapdor, Reudiger, Kluz, Tomasz , Konopka, Bożena , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lester, Jenny, Lubiński, Jan , Levine, Douglas A. , Lundvall, Lene, McGuire, Valerie , McNeish, Iain A. , Menon, Usha , Ness, Roberta B., Oršulić, Sandra , Pearce, Celeste Leigh, Ramus, Susan J. , Rothstein, Joseph H. , Rossing, Mary Anne, Rübner, Matthias, Schildkraut, Joellen M. , Schmalfeldt, Barbara , Schwaab, Ira, Sieh, Weiva , Sobiczewski, Piotr , Song, Honglin , Terry, Kathryn L. , Nieuwenhuysen, Els Van , Vanderstichele, Adriaan , Vergote, Ignace , Walsh, Christine , Webb, Penelope M. , Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Odunsi, Kunle , Chang‐Claude, Jenny , Goode, Ellen L. , Moysich, Kirsten B. , Dörk, Thilo , Bowtell, David D.L. , Lambrechts, Diether , Clay, Alyssa I, Hu, Qiang , Segal, Brahm H. , Anton‐Culver, Hoda , Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Cramer, Daniel W. , Dansonka‐Mieszkowska, Agnieszka , Dao, Fanny , Doherty, Jennifer A. , Bois, Andreas du , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Gronwald, Jacek , Karlan, Beth Y. , Kjær, Susanne K. , Modugno, Francesmary , Paul, James , Pejovic, Tanja B. , Pharoah, Paul D.P. , Siddiqui, Nadeem , Ziogas, Argyrios , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Ramus, Susan J , Vanderstichele, Adriaan , Webb, Penelope M , Hein, Alexander , Jensen, Allan , Eccles, Diana , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Diergaarde, Brenda , Lubinski, Jan , Kluz, Tomasz , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 28, 2016 | Volume: 26 | Issue: 3 | Pages: 420-424

10.1158/1055-9965.epi-16-0631 | PMID 27677730 Get It

Abstract Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival. Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing (P < 3.5 × 10−5), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival. Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes. Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. Cancer Epidemiol Biomarkers Prev; 26(3); 420–4. ©2016 AACR.
Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto, Rikki , LaMonte, Michael J. , Sucheston‐Campbell, Lara, Eng, Kevin H., Szender, J. Brian, Chang‐Claude, Jenny, Schmalfeldt, Barbara , Klapdor, R, Gower, Emily, Minlikeeva, Albina N. , Zirpoli, Gary , Edwards, Robert P., Goode, Ellen L. , Goodman, Marc T. , Høgdall, Estrid , Hosono, Satoyo , Jensen, Allan , Jordan, Susan J. , Group, on behalf of The Australian Ovarian Cancer Study, Matsuo, Keitaro , Ness, Roberta B., Olsen, Catherine M. , Olson, Sara H. , Pearce, Celeste Leigh , Pike, Malcolm C. , Rossing, Mary Anne, Szamreta, Elizabeth A. , Thompson, Pamela J., Tseng, Chiu-Chen , Vierkant, Robert A. , Webb, Penelope M. , Wentzensen, Nicolas , Wicklund, Kristine G. , Winham, Stacey J. , Wu, Anna H. , Schildkraut, Joellen M. , Terry, Kathryn L. , Kelemen, Linda E. , Moysich, Kirsten B. , Risch, Harvey A. , Hong, Chi‐Chen , Bandera, Elisa V. , Berchuck, Andrew , Cramer, Daniel W. , Doherty, Jennifer A. , Fridley, Brooke L. , Group, on behalf of The Australian Ovarian Cancer Study, Kjær, Susanne K. , Modugno, Francesmary , Winham, Stacey J , Webb, Penelope M , Jensen, Allan , Vierkant, Robert A , Moysich, Kirsten , Matsuo, Keitaro , Høgdall, Estrid , Zirpoli, Gary , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2016 | Volume: 25 | Issue: 7 | Pages: 1114-1124

10.1158/1055-9965.epi-15-1330 | PMID 27197285 Get It

Abstract Background: Despite a large body of literature evaluating the association between recreational physical activity and epithelial ovarian cancer (EOC) risk, the extant evidence is inconclusive, and little is known about the independent association between recreational physical inactivity and EOC risk. We conducted a pooled analysis of nine studies from the Ovarian Cancer Association Consortium to investigate the association between chronic recreational physical inactivity and EOC risk. Methods: In accordance with the 2008 Physical Activity Guidelines for Americans, women reporting no regular, weekly recreational physical activity were classified as inactive. Multivariable logistic regression was utilized to estimate the ORs and 95% confidence intervals (CI) for the association between inactivity and EOC risk overall and by subgroups based upon histotype, menopausal status, race, and body mass index. Results: The current analysis included data from 8,309 EOC patients and 12,612 controls. We observed a significant positive association between inactivity and EOC risk (OR = 1.34; 95% CI, 1.14–1.57), and similar associations were observed for each histotype. Conclusions: In this large pooled analysis examining the association between recreational physical inactivity and EOC risk, we observed consistent evidence of an association between chronic inactivity and all EOC histotypes. Impact: These data add to the growing body of evidence suggesting that inactivity is an independent risk factor for cancer. If the apparent association between inactivity and EOC risk is substantiated, additional work via targeted interventions should be pursued to characterize the dose of activity required to mitigate the risk of this highly fatal disease. Cancer Epidemiol Biomarkers Prev; 25(7); 1114–24. ©2016 AACR.